Tscan therapeutics appoints seasoned industry executive jason a. amello as chief financial officer

Waltham, mass., jan. 29, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of jason a. amello as chief financial officer. mr. amello, a senior finance executive, brings to tscan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.
TCRX Ratings Summary
TCRX Quant Ranking